Immunome Inc (IMNM)
15.75
+0.78
(+5.21%)
USD |
NASDAQ |
May 03, 16:00
16.05
+0.30
(+1.90%)
After-Hours: 20:00
Immunome Free Cash Flow (Quarterly): -17.81M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.81M |
| September 30, 2023 | -8.65M |
| June 30, 2023 | -6.008M |
| March 31, 2023 | 24.07M |
| December 31, 2022 | -6.755M |
| September 30, 2022 | -7.571M |
| June 30, 2022 | -8.23M |
| March 31, 2022 | -6.382M |
| Date | Value |
|---|---|
| December 31, 2021 | -6.819M |
| September 30, 2021 | -4.171M |
| June 30, 2021 | -3.749M |
| March 31, 2021 | -3.566M |
| December 31, 2020 | -6.108M |
| September 30, 2020 | -2.652M |
| June 30, 2020 | -1.841M |
| March 31, 2020 | -2.119M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-17.81M
Minimum
Dec 2023
24.07M
Maximum
Mar 2023
-4.273M
Average
-6.058M
Median
Free Cash Flow (Quarterly) Benchmarks
| Ayala Pharmaceuticals Inc | -- |
| Tenax Therapeutics Inc | -1.174M |
| GE HealthCare Technologies Inc | 274.00M |
| Exelixis Inc | 50.63M |
| Puma Biotechnology Inc | 10.41M |